Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Norcros annual underlying operating profit flat

(Sharecast News) - Norcros reported flat annual underlying operating profit on Thursday, despite a decline in revenue, as strong execution and improved margins in its core UK and Ireland business helped offset weaker trading in South Africa and the impact of divestments. Revenue for the year ended 31 March fell 6.1% to £368.1m, though on a constant currency like-for-like basis it rose 0.9%.

Underlying operating profit was unchanged at £43.2m, with the underlying margin improving to 11.7% from 11.0%.

Statutory operating profit dropped 79.2% to £8.3m, reflecting exceptional charges.

The London-listed bathroom products specialist said the UK and Ireland delivered a record underlying profit of £39.8m, up from £38.4m, with margins rising to 15.5%.

Performance in South Africa remained under pressure, with profit down to £3.4m from £4.8m, though Norcros said the business was positioned to benefit from market recovery.

The group continued to streamline its portfolio, selling Johnson Tiles UK in May last year and progressing a strategic review of its South African tile business.

It also expanded into complete bathroom ranges and improved cross-selling, while advancing distribution efficiency and ESG initiatives.

Underlying pre-tax profit edged up 0.3% to £36.5m, while diluted underlying earnings per share rose 0.9% to 32.4p.

The full-year dividend was lifted to 10.4p per share from 10.2p.

Underlying net debt stood at £36.8m, broadly flat on the prior year, representing a leverage ratio of 0.8x.

Looking ahead, Norcros reaffirmed its medium-term targets, including a 15% group operating margin and return on capital above 20%.

Current trading showed group revenue down 1.8% in the first two months of the new financial year, but the company left its expectations for the 2026 financial year unchanged despite continued market uncertainty.

"In the context of current market challenges, I am pleased with the performance over this period and excited by the significant opportunities that remain in the more resilient mid-premium market segments where we hold leading positions," said chief executive officer Thomas Willcocks.

"Our strategy is working and has momentum, building from a position of strength and scale as we actively leverage the customer and operational synergies within the group."

Willcocks said the firm's continued progress across its four key strategic pillars was delivering, as demonstrated by its operating margins in its core UK and Ireland markets moving above 15% for the first time.

"Whilst we are beginning to see some early evidence of a level of confidence starting to return to the sector, especially in new build, we are not reliant on any major recovery to deliver further progress against our medium term targets and as a result, the board's expectations for the 2026 financial year remain unchanged."

At 1134 BST, shares in Norcros were down 3.37% at 258p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.